SynthesisDiagnostic pathology2015
Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases.
Synthesis in Diagnostic pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Psychological Interventions in Chemotherapy-Induced Nausea and Vomiting in Women with Breast Cancer: A Systematic Review.Iranian journal of medical sciences · 2022Pooled it
- Diagnosis and Prognostic Significance of c-Met in Cervical Cancer: A Meta-Analysis.Disease markers · 2016Pooled it
- Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breast-conserving surgery: a long-term follow-up of the SweBCG91-RT randomised trial.Molecular oncology · 2020Trial
- Molecular imaging tracers targeting c-MET: a systematic review of preclinical evidence and clinical translation.European journal of nuclear medicine and molecular imaging · 2026Review
- C-MET tyrosine kinase receptor: mechanisms, clinical applications and future perspectives in cancer therapy.Signal transduction and targeted therapy · 2026Review
- Oleocanthal Induces Mitochondrial Dysfunction in Breast Cancer Cell Lines Depending on c-MET Expression.Antioxidants (Basel, Switzerland) · 2026Article
- Immunotherapy in Breast Cancer: Beyond Immune Checkpoint Inhibitors.International journal of molecular sciences · 2025Review
- Comparison of the effects of crizotinib as monotherapy and as combination therapy with butyric acid on different breast cancer cells.Oncology letters · 2025Article
- The Clinicopathological and Prognostic Significance of the Expression of PD-L1 and MET Genes in Breast Cancer: Potential Therapeutic Targets.Current cancer drug targets · 2025Article
- DIFFERENTIALLY EXPRESSED MIRNAS EXPLAIN RACIAL DIFFERENCES IN DIAGNOSIS STAGE AMONG TRIPLE NEGATIVE BREAST CANCER PATIENTS IN LOUISIANA.jLPHA : the official journal of the Louisiana Public Health Association · 2025Article
- Whole‑exome sequencing insights into synchronous bilateral breast cancer with discordant molecular subtypes.Oncology letters · 2024Article
- MET Oncogene Targeting for Cancer Immunotherapy.International journal of molecular sciences · 2024Review
- Liquid biopsy utilizing miRNA in patients with advanced breast cancer treated with cyclin‑dependent kinase 4/6 inhibitors.Oncology letters · 2024Article
- The Impact of the Coexpression ofThe breast journal · 2024Article
- Lupeol synergizes with 5-fluorouracil to combat c-MET/EphA2 mediated chemoresistance in triple negative breast cancer.iScience · 2023Article
- Quinacrine inhibits cMET-mediated metastasis and angiogenesis in breast cancer stem cells.Journal of cell communication and signaling · 2023Article
- Propolis-loaded nanostructured lipid carriers halt breast cancer progression through miRNA-223 related pathways: an in-vitro/in-vivo experiment.Scientific reports · 2023Article
- Article
- Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis.Journal of clinical medicine · 2022Article
- Combined Expression of HGFR with Her2/neu, EGFR, IGF1R, Mucin-1 and Integrin α2β1 Is Associated with Aggressive Epithelial Ovarian Cancer.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic value of c-Met in breast cancer remains controversial. A meta-analysis of the impact of c-Met in breast cancer was performed by searching published data.
methodsPublished studies analyzing overall survival (OS) or relapse free survival (RFS) according to c-Met expression were searched. The principal outcome measures were hazard ratios (HRs) for RFS or OS according to c-Met expression. Combined HRs were calculated using fixed- or random- effects models according to the heterogeneity.
resultsTwenty-one studies involving 6,010 patients met our selection criteria. The impact of c-Met on RFS and OS was investigated in 12 and 17 studies, respectively. The meta-analysis results showed that c-Met overexpression significantly predicted poor RFS and OS in unselected breast cancer. Subgroup analysis indicated that c-Met overexpression was correlated with poor RFS and OS in Western patients, but was not associated with RFS or OS in Asian patients. C-Met was associated with poor OS in lymph node negative breast cancer and with poor RFS in hormone-receptor positive and triple negative breast cancer, but was not associated with prognosis in human epidermal growth factor receptor (HER)-2 positive breast cancer.
conclusionsC-Met overexpression is an adverse prognostic marker in breast cancer, except among Asian and HER-2 positive patients. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1869780799156041.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.